QNRX has established a worldwide sales network to prepare for its expected market launch of QRX003, as it advances clinical studies towards a potential New Drug Application. Quoin expects to report topline data from two pivotal clinical studies for QRX003 in Netherton Syndrome (NS) in 2H 2026. Clinical data thus far has demonstrated clear evidence of rapid, prolonged and almost complete skin healing, along with the almost complete elimination of key symptoms, following twice-daily application of QRX003 to the treatment areas. The company believes QRX003 is on track potentially to become the first approved treatment for NS.